Increasing mupirocin resistance of Staphylococcus aureus in CAPD--should it continue to be used as prophylaxis?

This editorial summarizes the mechanisms of mupirocin resistance and the conditions that promote its development. While there is increasing evidence that high-level mupirocin resistance is developing during systematic use of mupirocin as prophylaxis against Staphylococcus aureus, the appearance of r...

Full description

Saved in:

Bibliographic Details
Published in:	Peritoneal dialysis international Vol. 22; no. 6; pp. 649 - 652
Main Authors:	Conly, JM, Vas, S
Format:	Journal Article
Language:	English
Published:	United States 01-11-2002
Subjects:	Anti-Bacterial Agents - therapeutic use Antibiotic Prophylaxis - adverse effects Drug Resistance, Bacterial - physiology Humans Mupirocin - therapeutic use Peritoneal Dialysis, Continuous Ambulatory - adverse effects Staphylococcal Infections - etiology Staphylococcal Infections - physiopathology Staphylococcal Infections - prevention & control Staphylococcus aureus - drug effects Staphylococcus aureus - physiology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This editorial summarizes the mechanisms of mupirocin resistance and the conditions that promote its development. While there is increasing evidence that high-level mupirocin resistance is developing during systematic use of mupirocin as prophylaxis against Staphylococcus aureus, the appearance of resistance does not preclude the beneficial effect of regular prophylaxis. Vigilance has to be exercised to notice larger-scale resistance that may require limiting the use of mupirocin.
ISSN:	0896-8608 1718-4304
DOI:	10.1177/089686080202200601